Approval summary for bortezomib for injection in the treatment of multiple myeloma.
Bross
Peter F
PF
Division of Oncology Drug Products, Center for Drug Evaluation and Research, United States Food and Drug Administration, Rockville, Maryland, USA. bross@cber.fda.gov
Kane
Robert
R
Farrell
Ann T
AT
Abraham
Sophia
S
Benson
Kimberly
K
Brower
Margaret E
ME
Bradley
Sean
S
Gobburu
Jogarao V
JV
Goheer
Anwar
A
Lee
Shwu-Luan
SL
Leighton
John
J
Liang
Cheng Yi
CY
Lostritto
Richard T
RT
McGuinn
William D
WD
Morse
David E
DE
Rahman
Atiqur
A
Rosario
Lilliam A
LA
Verbois
S Leigh
SL
Williams
Grant
G
Wang
Yong-Cheng
YC
Pazdur
Richard
R
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D002986:Clinical Trials as Topic; D017277:Drug Approval; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008956:Models, Chemical; D009101:Multiple Myeloma / Q000188:drug therapy*; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D011719:Pyrazines / Q000627:therapeutic use*; D013997:Time Factors; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D046988:Proteasome Endopeptidase Complex